American Association for Cancer Research

Table 1

Antitumor activity and toxicity of different schedules of topotecan administered i.p. in mice

Group of animals	Schedule of administration^a	Toxic death (%)	Maximum weight loss (%)	Cured mice (%)
1	12.5 mg/kg × 1	0	4	16.67
2	2.5 mg/kg d × 5^b	33.3	27	33.33
3	1.25 mg/kg (d × 5)2^b	16.67	12	83.33
4	0.625 mg/kg (d × 5)4^b	0	3	100
5	0.312 mg/kg (d × 5)8^b	0	0.15	50
6	0.156 mg/kg (d × 5)16^b	0	0	33.33
7	1.25 mg/kg (d × 5)q2w^c	0	18	16.67
8	0.625 mg/kg [(d × 5)q2w]2^c	0	5	50

Group of animals	Schedule of administration^a	Toxic death (%)	Maximum weight loss (%)	Cured mice (%)
1	12.5 mg/kg × 1	0	4	16.67
2	2.5 mg/kg d × 5^b	33.3	27	33.33
3	1.25 mg/kg (d × 5)2^b	16.67	12	83.33
4	0.625 mg/kg (d × 5)4^b	0	3	100
5	0.312 mg/kg (d × 5)8^b	0	0.15	50
6	0.156 mg/kg (d × 5)16^b	0	0	33.33
7	1.25 mg/kg (d × 5)q2w^c	0	18	16.67
8	0.625 mg/kg [(d × 5)q2w]2^c	0	5	50

Topotecan treatment began 3 days after tumor implantation.

Topotecan was administered i.p. 5 days/week, for 1, 2, 4, 8, or 16 consecutive weeks.

Topotecan was administered i.p. 5 days/week every other week for a total of 4 or 8 weeks.